| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99444 |
|
7,539 |
1,924 |
$429K |
| 99214 |
|
11,138 |
8,290 |
$258K |
| 99213 |
|
4,424 |
3,637 |
$104K |
| 90792 |
|
578 |
562 |
$60K |
| 99421 |
|
2,595 |
659 |
$41K |
| 87426 |
|
483 |
431 |
$17K |
| 90833 |
|
205 |
173 |
$8K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
31 |
31 |
$8K |
| 99202 |
|
260 |
254 |
$8K |
| 95927 |
|
363 |
363 |
$7K |
| 96372 |
|
754 |
677 |
$6K |
| 95165 |
|
292 |
53 |
$5K |
| 95943 |
|
363 |
363 |
$4K |
| 99212 |
|
203 |
169 |
$4K |
| 95004 |
|
41 |
40 |
$3K |
| G0179 |
Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care |
973 |
972 |
$2K |
| 93922 |
|
361 |
361 |
$1K |
| 0071A |
|
26 |
26 |
$960.00 |
| 0001A |
|
31 |
31 |
$858.00 |
| 99203 |
|
14 |
14 |
$723.96 |
| 0004A |
|
17 |
17 |
$638.00 |
| 93000 |
|
120 |
117 |
$531.70 |
| 0002A |
|
20 |
20 |
$514.00 |
| 99211 |
|
33 |
33 |
$433.07 |
| 99215 |
Prolong outpt/office vis |
41 |
39 |
$418.38 |
| 0072A |
|
14 |
14 |
$400.00 |
| 90686 |
|
52 |
52 |
$372.57 |
| 99091 |
|
813 |
767 |
$312.86 |
| 94640 |
|
44 |
40 |
$156.66 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
223 |
211 |
$149.55 |
| 81002 |
|
250 |
210 |
$137.74 |
| S8301 |
Infection control supplies, not otherwise specified |
26 |
24 |
$115.49 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
83 |
77 |
$34.25 |
| 82962 |
|
966 |
795 |
$25.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
31 |
30 |
$7.01 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
13 |
13 |
$0.21 |
| 91301 |
|
72 |
71 |
$0.02 |
| 95117 |
|
62 |
24 |
$0.00 |
| 3017F |
|
303 |
268 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
4,680 |
3,367 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
767 |
706 |
$0.00 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
92 |
91 |
$0.00 |
| 3044F |
|
47 |
40 |
$0.00 |
| 1036F |
|
888 |
810 |
$0.00 |
| G9717 |
Documentation stating the patient has had a diagnosis of bipolar disorder |
246 |
217 |
$0.00 |
| 0509F |
|
126 |
123 |
$0.00 |
| 91307 |
|
40 |
40 |
$0.00 |
| 1124F |
|
629 |
578 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
3,480 |
2,631 |
$0.00 |
| 4040F |
|
487 |
443 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
6,112 |
4,369 |
$0.00 |
| G8482 |
Influenza immunization administered or previously received |
597 |
526 |
$0.00 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
1,142 |
955 |
$0.00 |
| G8483 |
Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) |
372 |
361 |
$0.00 |
| 3045F |
|
41 |
34 |
$0.00 |
| G9899 |
Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results documented and reviewed |
86 |
83 |
$0.00 |
| G8399 |
Patient with documented results of a central dual-energy x-ray absorptiometry (dxa) ever being performed |
169 |
158 |
$0.00 |
| Q0243 |
Injection, casirivimab and imdevimab, 2400 mg |
31 |
31 |
$0.00 |
| 3046F |
|
462 |
427 |
$0.00 |
| 91300 |
|
69 |
69 |
$0.00 |
| G0246 |
Follow-up physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (lops) to include at least the following: (1) a patient history, (2) a physical examination that includes: (a) visual inspection of the forefoot, hindfoot and toe web spaces, (b) evaluation of protective sensation, (c) evaluation of foot structure and biomechanics, (d) evaluation of vascular status and skin integrity, and (e) evaluation and recommendation of footwear, and (3) patient education |
26 |
26 |
$0.00 |
| G8400 |
Patient with central dual-energy x-ray absorptiometry (dxa) results not documented, reason not given |
19 |
14 |
$0.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
94 |
92 |
$0.00 |
| G9900 |
Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results were not documented and reviewed, reason not otherwise specified |
21 |
19 |
$0.00 |
| 4004F |
|
32 |
22 |
$0.00 |